12:00 AM
Oct 18, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

INX-3280: Phase I testing update

Inex Pharmaceuticals Corp. (TSE:IEX), Vancouver, B.C.
Product: INX-3280
Business: Cancer
Therapeutic category: Antisense
Target: C-myc RNA...

Read the full 69 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >